Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (151-160 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|August 9, 2013
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 studyRuth Ladenstein, Silke Weixler, Bianca Baykan, et al.
Mabs|April 23, 2011
Biosimilars 2.0: guiding principles for a global "patients first" standardJoseph Miletich, Geoffrey Eich, Gustavo Grampp, et al.
Mabs|August 5, 2011
Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancerDaniel C Julien, Steven Behnke, Guankui Wang, et al.
Mabs|August 9, 2011
Infections associated with monoclonal antibody and fusion protein therapy in humansFlorence Uettwiller, Emilie Rigal, Cyrille Hoarau
Mabs|July 26, 2011
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodiesAlain Beck, Janice M Reichert
Mabs|March 29, 2012
Improved stability of multivalent antibodies containing the human collagen XV trimerization domainAngel M Cuesta, David Sánchez-Martín, Ana Blanco-Toribio, et al.
Mabs|March 29, 2012
Dual targeting strategies with bispecific antibodiesRoland E Kontermann
Mabs|November 30, 2011
Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture mediaTimothy Kaschak, Daniel Boyd, Franklin Lu, et al.
Mabs|February 14, 2012
Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological functionHongcheng Liu, Kimberly May
Mabs|February 14, 2012
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targetingIngo Schubert, Christian Kellner, Christoph Stein, et al.
Pageof 184

Showing results (151-160 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|August 9, 2013
Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 studyRuth Ladenstein, Silke Weixler, Bianca Baykan, et al.
Mabs|April 23, 2011
Biosimilars 2.0: guiding principles for a global "patients first" standardJoseph Miletich, Geoffrey Eich, Gustavo Grampp, et al.
Mabs|August 5, 2011
Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancerDaniel C Julien, Steven Behnke, Guankui Wang, et al.
Mabs|August 9, 2011
Infections associated with monoclonal antibody and fusion protein therapy in humansFlorence Uettwiller, Emilie Rigal, Cyrille Hoarau
Mabs|July 26, 2011
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodiesAlain Beck, Janice M Reichert
Mabs|March 29, 2012
Improved stability of multivalent antibodies containing the human collagen XV trimerization domainAngel M Cuesta, David Sánchez-Martín, Ana Blanco-Toribio, et al.
Mabs|March 29, 2012
Dual targeting strategies with bispecific antibodiesRoland E Kontermann
Mabs|November 30, 2011
Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture mediaTimothy Kaschak, Daniel Boyd, Franklin Lu, et al.
Mabs|February 14, 2012
Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological functionHongcheng Liu, Kimberly May
Mabs|February 14, 2012
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targetingIngo Schubert, Christian Kellner, Christoph Stein, et al.
Pageof 184